-

ZOLL Reports Email Phishing Attack

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (“ZOLL”) is notifying individuals who were in contact with ZOLL Respicardia either directly or indirectly through a provider, or whose provider contacted ZOLL Respicardia on their behalf, that their health information may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack. This incident was limited to emails and had no impact on ZOLL’s medical devices, software, or services. The information affected by the incident may have included some individuals’ names and health information. ZOLL has no indication that the information has been misused. ZOLL is evaluating its cybersecurity education and training measures for employees. Individuals with questions can contact a dedicated call center at 800-459-4255 Monday through Friday from 8 a.m. to 8 p.m. CST, closed Saturday and Sunday (and excluding major U.S. holidays).

Contacts

Matt Hogan
ZOLL
+1 (978) 805-6561
media@zoll.com

ZOLL Medical Corporation


Release Versions

Contacts

Matt Hogan
ZOLL
+1 (978) 805-6561
media@zoll.com

More News From ZOLL Medical Corporation

ZOLL® Expands “Anything Can Happen. Anyone Can Help.”™ to Strengthen Cardiac Emergency Readiness Across Youth Sports Nationwide

CHELMSFORD, Mass.--(BUSINESS WIRE)--From local fields to national venues, youth sports play out every day across the country. Today, ZOLL® Medical, an Asahi Kasei company, announced the next phase of its national Anything Can Happen. Anyone Can Help.™ campaign, aimed at strengthening cardiac emergency readiness where young athletes play. Sudden cardiac arrest remains the leading cause of death among young athletes1, and approximately 356,000 out-of-hospital cardiac arrests occur nationwide each...

New Data: LifeVest® Wearable Defibrillator is Useful Tool for Quicker Beta-Blocker Optimization in Women

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that insights from the LifeVest® wearable cardioverter defibrillator (WCD) helped physicians achieve better heart rate control in female patients – an indicator of more rapid beta-blocker optimization and an outcome associated with improved survival. These findings come from the Optimizing Beta‑Blocker Dosage in Female Patients Using the Wearable Cardiove...

Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, will highlight the latest sudden cardiac death research, case experiences for heart failure readmission reduction, and two Innovation Stage presentations at the American College of Cardiology Annual Scientific Session & Expo (ACC.26), March 28-30, 2026. ZOLL will sponsor a slate of educational programs to engage and connect clinicians with emerging evidence and...
Back to Newsroom